Independent education resourceInformation here does not replace care from a qualified health professional.
Peptide Therapy GuideClear peptide education

Educational guide

Syn-Ake

Syn-Ake MolecularFormula | C23H37N5O7 / MolecularWeight | 495.6 / IUPACName | acetic acid;(2S)-N-[(2S)-4-amino-1-(benzylamino)-1-oxobutan-2-yl]-1-(3-aminopropanoyl)pyrrolidine-2-carboxamide 823202-99-9 | Syn-ake | Dipeptide diaminobutyroyl benzylamide diacetat

Written by Peptide Therapy Guide Editorial Team
For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

Syn-Ake

MolecularFormulaC23H37N5O7
MolecularWeight495.6
IUPACNameacetic acid;(2S)-N-[(2S)-4-amino-1-(benzylamino)-1-oxobutan-2-yl]-1-(3-aminopropanoyl)pyrrolidine-2-carboxamide
  • 823202-99-9
  • Syn-ake
  • Dipeptide diaminobutyroyl benzylamide diacetate
  • 38H206R00R
  • UNII-38H206R00R
  • DTXSID40231699
  • Dipeptide diaminobutyroyl benzylamide diacetate [INCI]
  • Butanamide, beta-alanyl-L-prolyl-2,4-diamino-N-(phenylmethyl)-, (2S)-, acetate (1:2)
  • Butanamide, beta-alanyl-L-prolyl-2,4-diamino-N-(phenylmethyl)-, (2S)-, diacetate
  • BUTANAMIDE, .BETA.-ALANYL-L-PROLYL-2,4-DIAMINO-N-(PHENYLMETHYL)-, (2S)-, DIACETATE
  • BUTANAMIDE, .BETA.-ALANYL-L-PROLYL-2,4-DIAMINO-N-(PHENYLMETHYL)-, (2S)-, ACETATE (1:2)
  • RefChem:134618
  • DTXCID20154190
  • Syn-Ake acetate
  • (2S)-beta-Alanyl-L-prolyl-2,4-diamino-N-(phenylmethyl)butanamide acetate
  • SYN-AKE Diacetate
  • acetic acid;(2S)-N-[(2S)-4-amino-1-(benzylamino)-1-oxobutan-2-yl]-1-(3-aminopropanoyl)pyrrolidine-2-carboxamide
  • Dipeptide diaminobutyroyl benzylamide (diacetate)
  • (S)-N-((S)-4-amino-1-(benzylamino)-1-oxobutan-2-yl)-1-(3-aminopropanoyl)pyrrolidine-2-carboxamide diacetate
  • Serpent Peptide 2AcOH
  • SYN-AK
  • orb1299405
  • SCHEMBL29374327
  • betaAla-Pro-Dab-NHBn.2CH3CO2H
  • C23H37N5O7
  • EX-A3743
  • HY-P0102
  • H-|A-Ala-Pro-Dab-NH-Bzl.2AcOH
  • H-beta-Ala-Pro-Dab-NH-Bzl.2AcOH
  • (2S)-beta-Alanyl-L-prolyl-2,4-diamino-N-(phenylmethyl)butanamideacetate
  • AS-83264
  • DA-58213
  • FA151450
  • PD069794
  • CS-0017931
  • T7895
  • D92813
  • Dipeptide diaminobutyroyl benzylamide (acetate)
  • Q27256785
  • Dipeptide Diaminobutyroyl Benzylamide Diacetate (Liquid)

Connected reading

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Practical and safety references

These excerpts are educational, not personalised medical instructions.

Potential benefits

Primary Benefits

Achieves 26-30% wrinkle reduction within 3 weeks through competitive nAChR blockade, with immediate smoothing effects visible within 24 hours of first application. 3,700-fold selectivity for the alpha-epsilon nAChR subunit interface provides highly targeted muscle-type receptor blockade without affecting neuronal nicotinic receptors. Beyond neuromuscular action, demonstrates MMP inhibition (collagen protection), SIRT1 activation (cellular longevity), and antioxidant DPPH radical scavenging.

Source: peptideinitiative.com ↗
P

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Continue learning

Related guides